March
31
2021
Prevent Blindness applauds FDA’s decision to allow production of thyroid eye disease treatment to resume
As a result of direct patient advocacy to the U.S. Food and Drug Administration (FDA) through Prevent Blindness, patients will be able to resume their treatments for thyroid eye disease